Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
New studies of old dogs help scientists understand where they came from - 2My Excursion to Monetary Autonomy: Awesome ways to save cash
- 3Find the Marvels of the World with These Travels
- 4Satellite constellations could obscure most space telescope observations by late 2030s: 'That part of the image will be forever lost'
- 5These 3 Nail-Free Finds Completely Transformed My Drab Bathroom
- Passenger Missing After Going Overboard Disney Cruise Ship
- Instructions to Expand Your Advantages from an Open Record Reward
- Eight wounded, cars catch fire in central Israel following strike from Iranian cluster munition
- 35 million tons of food go to waste yearly in the US. Experts share tips to help stop it
- 'We were genuinely astonished': This moss survived 9 months outside the International Space Station and could still grow on Earth
- 'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn
- Promising Speculation Bearings for Portfolio Development in 2024
- Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- IDF destroys two-kilometer-long Gaza terror tunnel in Beit Lahiya
